Program length (60 minutes)
- Welcome and Introduction
- Achieving Deep Remission IBD: A Call to Action
- Guideline Recommendations for Optimizing UC/CD Therapy
- New and Emerging Therapies for IBD
- Treatment De-escalation
- Audience Question and Answer Session
Uma Mahadevan, MD
Professor of Medicine
Division of Gastroenterology
Department of Medicine
University of California, San Francisco
UCSF Center for Colitis and Crohn's Disease
San Francisco, California
The goal of this activity is to improve clinicians’ competence in navigating the most challenging clinical issues to help ensure successful IBD care.
This program is intended for gastroenterologists, advanced practice clinicians, and other healthcare providers who care for patients with IBD.
At the conclusion of this activity, learners should be able to:
- Develop initial IBD treatment strategies with the goal to achieve early deep remission in patients with moderate to severe disease
- Consider the latest outcomes data on non-TNF inhibitor biologics or JAK inhibitors when considering switch therapy for patients who do not achieve sustained remission with conventional or TNF inhibitor regimens
- Compare and contrast JAK inhibitor selectivity for specific JAK enzymes and how these distinctions may potentially relate to safety outcomes
- Explore evidence-based strategies for IBD treatment de-escalation that may include dose reduction or drug discontinuation once sustained remission has been achieved
Physician Continuing Medical Education
American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The American Gastroenterological Association (AGA) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the AGA policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.